Aliphatic Acid Amide Derivative for Dual 5-HT2A/5-HT7 Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no commercial drugs with selective antagonist activity for both the serotonin 5-HT 2A and 5-HT 7 receptors, limiting their effectiveness in treating neuropsychiatric diseases.
Innovation Solution
Development of a compound with Formula (1) or its pharmaceutically acceptable salt, which exhibits antagonist activity for both the serotonin 5-HT 2A and 5-HT 7 receptors, useful as a medicament for treating neuropsychiatric diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate drugs targeting 5-HT2A or 5-HT7 receptors are used, then specific receptor antagonism is achieved, but dual receptor coverage is limited
Solution Approach 1:
The patent combines two separate therapeutic functions (5-HT2A antagonism and 5-HT7 antagonism) into a single compound (Formula 1). This merging approach allows the drug to simultaneously target both receptors, providing dual coverage that was previously only achievable through combination therapy with separate agents.
Solution Approach 2:
The compound of Formula 1 is designed as a multi-functional agent that exhibits antagonist activity against both 5-HT2A and 5-HT7 receptors. This universal design enables a single medication to address multiple neuropsychiatric conditions or provide synergistic effects, enhancing versatility while maintaining reliable receptor antagonism.
2Ease of manufacture
If existing commercial drugs are used, then ease of availability is maintained, but selective dual antagonist activity is lacking
Solution Approach 1:
The patent introduces a novel chemical structure (Formula 1) with specific structural parameters that enable simultaneous binding to both 5-HT2A and 5-HT7 receptors. By optimizing molecular parameters such as the core heterocyclic structure, substituent groups, and spatial configuration, the compound achieves selective dual antagonist activity that distinguishes it from existing commercial drugs.
3Reliability
If combination therapy with multiple drugs is used, then treatment efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges the functions of multiple drugs into a single compound, reducing treatment complexity. Instead of requiring patients to take separate medications for 5-HT2A and 5-HT7 receptor targeting, the compound of Formula 1 provides both therapeutic effects in one agent, simplifying the treatment regimen while maintaining enhanced efficacy.
Solution Approach 2:
The multi-functional compound serves as a universal treatment option that can replace combination therapy. By incorporating both 5-HT2A and 5-HT7 antagonist activities in one molecule, it provides a simplified yet effective treatment approach for neuropsychiatric disorders, reducing the complexity associated with managing multiple medications.
Data Source
Figure 1~2
Figure 3
AI summary
The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.)